Endocrine Reviews – Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease (2022) Julian M. Yabut

Description

This review analyzes the use of Glucagon-like Peptide-1 receptor agonists (GLP-1RA) for treating type 2 diabetes and obesity, highlighting their considerable potential to reduce hepatic inflammation, steatosis, and fibrosis. The text discusses evolving concepts of GLP-1 action that improve liver health, focusing on the therapeutic potential of GLP-1RA for metabolic associated fatty liver disease (MAFLD) and nonalcoholic steatohepatitis (NASH).